Castle Biosciences (CSTL) Research & Development (2018 - 2026)

Castle Biosciences has disclosed Research & Development across 9 years of filings, most recently posting $14.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $14.4 million, up 14.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.7 million (up 5.65% YoY), and the FY2025 annual result was $51.8 million, changed 0.37% from the prior year.
• Research & Development came in at $14.4 million for Q1 2026 at Castle Biosciences, up from $13.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $14.4 million in Q1 2026 to a low of $10.8 million in Q1 2022.
• The 5-year median for Research & Development is $12.9 million (2023), against an average of $12.8 million.
• Across the five-year window, Research & Development soared 82.14% in 2022 and dropped 9.54% in 2025, its largest moves.
• Castle Biosciences' Research & Development stood at $11.3 million in 2022, then rose by 14.9% to $13.0 million in 2023, then slipped by 9.4% to $11.8 million in 2024, then advanced by 14.8% to $13.5 million in 2025, then rose by 6.76% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q1 2026), $13.5 million (Q4 2025), and $13.0 million (Q3 2025), per Business Quant data.